What are the recommended inpatient orders for managing community‑acquired pneumonia, including empiric antibiotic regimen, laboratory and imaging studies, monitoring, and supportive care?

Inpatient Community-Acquired Pneumonia Orders

For non-ICU inpatients with community-acquired pneumonia, initiate either a respiratory fluoroquinolone (levofloxacin 750 mg IV daily, moxifloxacin 400 mg IV daily) OR a β-lactam (ceftriaxone 1-2g IV daily or cefotaxime 1-2g IV q8h) plus a macrolide (azithromycin 500 mg IV daily). 1

Empiric Antibiotic Regimen

Non-ICU Patients (Standard Risk)

Choose ONE of the following regimens:

Option 1: Respiratory Fluoroquinolone Monotherapy

• Levofloxacin 750 mg IV daily, OR
• Moxifloxacin 400 mg IV daily

Option 2: β-lactam PLUS Macrolide Combination

• Ceftriaxone 1-2g IV daily OR cefotaxime 1-2g IV q8h OR ampicillin-sulbactam 3g IV q6h
• PLUS azithromycin 500 mg IV daily (or doxycycline 100 mg IV q12h as alternative)

Both regimens have strong evidence (Level I) and are equally effective for mortality reduction. 1

ICU Patients (Severe CAP)

Mandatory combination therapy:

• β-lactam (ceftriaxone 2g IV daily OR cefotaxime 2g IV q8h OR ampicillin-sulbactam 3g IV q6h)
• PLUS azithromycin 500 mg IV daily OR respiratory fluoroquinolone

Add MRSA coverage if:

• Necrotizing/cavitary infiltrates
• Empyema present
• Post-influenza pneumonia
• Prior MRSA infection

If MRSA coverage needed: Add vancomycin 15 mg/kg IV q8-12h (target trough 15-20 mg/mL) OR linezolid 600 mg IV q12h 2, 1, 2

Add Pseudomonas coverage if:

• Structural lung disease (bronchiectasis, cystic fibrosis)
• Recent hospitalization with IV antibiotics in past 90 days
• Severe immunosuppression

If Pseudomonas coverage needed: Use antipseudomonal β-lactam (piperacillin-tazobactam 4.5g IV q6h, cefepime 2g IV q8h, imipenem 500mg IV q6h, or meropenem 1g IV q8h) PLUS ciprofloxacin 400 mg IV q8h OR levofloxacin 750 mg IV daily PLUS aminoglycoside 1

Laboratory Studies

Initial Labs (All Patients):

• Complete blood count with differential
• Basic metabolic panel (electrolytes, BUN, creatinine, glucose)
• Liver function tests
• Arterial blood gas or pulse oximetry
• Two sets of blood cultures (before antibiotics)

Additional Testing for Severe CAP or ICU Admission:

• Sputum Gram stain and culture (if productive cough and quality specimen obtainable)
• Legionella urinary antigen
• Pneumococcal urinary antigen
• Endotracheal aspirate (if intubated)
• Consider procalcitonin for severity assessment 1

Optional for non-severe cases: Blood and sputum cultures may be omitted in low-risk patients without specific indications 1

Imaging Studies

Chest X-ray (PA and lateral): Required for diagnosis confirmation and to identify complications (pleural effusion, multilobar involvement, cavitation) 1

Follow-up imaging: Not routinely needed if clinical improvement occurs. Consider repeat chest X-ray at 6-8 weeks only if:

• Persistent symptoms
• Age >50 with smoking history (to exclude underlying malignancy)
• Slow clinical response

Monitoring Parameters

Daily assessments:

• Vital signs every 4-6 hours (temperature, heart rate, respiratory rate, blood pressure, oxygen saturation)
• Clinical stability criteria: Temperature ≤37.8°C, heart rate ≤100 bpm, respiratory rate ≤24/min, systolic BP ≥90 mmHg, oxygen saturation ≥90% on room air, ability to take oral medications

Laboratory monitoring:

• Repeat basic metabolic panel if renal dysfunction or electrolyte abnormalities
• If vancomycin used: Trough levels before 4th dose (target 15-20 mg/mL)
• Repeat blood cultures if persistent fever after 48-72 hours

Supportive Care

Oxygen therapy: Maintain SpO₂ ≥90% (≥88% if COPD)

IV fluids: Isotonic crystalloids for hypotension or dehydration; avoid overhydration

Venous thromboembolism prophylaxis:

• Pharmacologic prophylaxis (enoxaparin 40 mg SC daily or heparin 5000 units SC q8-12h) unless contraindicated
• Mechanical prophylaxis if bleeding risk

Nutrition: Early oral intake as tolerated; nutritional supplementation if prolonged illness

Mobilization: Early ambulation when clinically stable

Transition to Oral Therapy

Switch from IV to oral antibiotics when ALL criteria met:

• Hemodynamically stable
• Improving clinically
• Afebrile for 48-72 hours
• Able to take oral medications
• Normal gastrointestinal function
• No more than 1 CAP-associated sign of clinical instability

Typically occurs within 2-3 days. 1

Duration of Therapy

Minimum 5 days of antibiotics if patient is:

• Afebrile for 48-72 hours AND
• Has no more than 1 sign of clinical instability

Most patients require 5-7 days total. Longer courses (up to 14-21 days) only for complications like empyema, lung abscess, or bacteremia. 1

Critical Pitfalls to Avoid

• Do NOT delay antibiotics for diagnostic testing—first dose should be given in the emergency department within 4-6 hours of presentation 1
• Do NOT use macrolide monotherapy for hospitalized patients—resistance rates make this inadequate 1
• Do NOT continue empiric MRSA coverage if cultures negative at 48-72 hours
• Do NOT use two β-lactams together—no added benefit and increases toxicity risk 3
• Do NOT withhold antibiotics if viral testing is positive—bacterial co-infection is common and outcomes worsen without antibacterial therapy 4

Discharge Planning

Before discharge, ensure:

• Pneumococcal vaccination (PPSV23 and PCV13/PCV15/PCV20 per age-appropriate schedule)
• Influenza vaccination (if during flu season)
• Smoking cessation counseling and resources
• Follow-up appointment within 1-2 weeks